EcoDrugPlus

Neuropeptide Y Receptor Type 2-Like

Ensembl ID : ENSACLG00000016028
Gene Symbol: LOC113019440
3 Cross references
176 Possible Orthologues:

Neuropeptide Y Receptor Type 4-Like

Ensembl ID : ENSACLG00000006106
Gene Symbol: LOC113034524
3 Cross references
137 Possible Orthologues:

Neurotensin Receptor 1

Ensembl ID : ENSACLG00000006863
Gene Symbol: NTSR1
3 Cross references
199 Possible Orthologues:

Neurotrophic Receptor Tyrosine Kinase 2

Ensembl ID : ENSACLG00000018347
Gene Symbol: NTRK2
3 Cross references
208 Possible Orthologues:

Neurotrophic Receptor Tyrosine Kinase 3

Ensembl ID : ENSACLG00000014805
Gene Symbol: NTRK3
4 Cross references
183 Possible Orthologues:

Neurotrophic Receptor Tyrosine Kinase 3

Ensembl ID : ENSACLG00000019754
Gene Symbol: NTRK3
3 Cross references
203 Possible Orthologues:

Neurotrophic Tyrosine Kinase, Receptor, Type 1

Ensembl ID : ENSACLG00000009587
Gene Symbol: NTRK1
1 Cross references
200 Possible Orthologues:

Neurotrophic Tyrosine Kinase, Receptor, Type 2b

Ensembl ID : ENSACLG00000001584
Gene Symbol: NTRK2B
1 Cross references
178 Possible Orthologues:

Neurotrophic Tyrosine Kinase, Receptor, Type 2b

Ensembl ID : ENSACLG00000001565
Gene Symbol: NTRK2B
1 Cross references
203 Possible Orthologues:

Nicastrin

Ensembl ID : ENSACLG00000004838
Gene Symbol: NCSTN
4 Cross references
204 Possible Orthologues:

Nicotinamide Phosphoribosyltransferase

Ensembl ID : ENSACLG00000000655
Gene Symbol: NAMPT
3 Cross references
219 Possible Orthologues:

Nischarin

Ensembl ID : ENSACLG00000004780
Gene Symbol: NISCH
2 Cross references
209 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).